Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CABRAMET trial: what clinicians have said so far
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
- NCT03967522 ↗
- Completed
- Centre Leon Berard
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CABRAMET (cabozantinib in metastatic renal cell carcinoma with brain metastases) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CABRAMET so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- CABRAMET: A Phase 2 Study of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Cabozantinib
- Arms
- Cabozantinib treatment · Experimental
- Enrollment
- 26
- Primary outcomes
- The non progression rate in brain metastases at 6 months
- Sponsor
- Centre Leon Berard
- Start
- Nov 29, 2019
- Primary completion
- Oct 22, 2024
- Results posted
- No
- Registry record
- NCT03967522 · updated Aug 8, 2025
Publications
linked from the registry- Negrier S, Mourey L, Dalban C, Gross-Goupil M, Flechon A, Escudier B, Barthelemy P, Oudard S, Colomba E, Thibault C, Ravaud A, Chevreau C, Boyle HJ, Blanc E, Chabaud S, Perol D, Albiges L, Flippot R; Groupe d'Etude des Tumeurs UroGenitale (Urogenital Tumor Study Group, GETUG) investigators. Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET. Eur J Cancer. 2026 May 15;239:116712. doi: 10.1016/j.ejca.2026.116712. Epub 2026 Apr 1. PubMed 41946178